00:01 , May 23, 2019 |  BioCentury  |  Finance

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

Preclinical data supporting its RNA-targeting gene therapy platform enabled Locana to attract $55 million in series A funding led by existing investor Arch Venture Partners, which the San Diego company plans to use to bring...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Juno Therapeutics, Celgene deal

Juno said it has an agreement in principle to grant Celgene a license to a subset of the technology Juno gained through its acquisition of AbVitro Inc. and options to gain rights to potential products...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

AbVitro, Juno Therapeutics deal

Juno acquired AbVitro, gaining AbVitro’s high throughput, single-cell sequencing platform that enables identification of natively paired T cell receptors (TCRs) and chimeric antigen receptor (CAR) T cell binders. Juno said it will use AbVitro’s technology...
02:45 , Jan 12, 2016 |  BC Extra  |  Company News

Juno acquires sequencing play AbVitro

Juno Therapeutics Inc. (NASDAQ:JUNO) acquired next-generation sequencing company AbVitro Inc. (Boston, Mass.) for about $125 million, including about $78 million in cash up front plus 1.3 million Juno shares. The Juno shares are valued at...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

AbVitro, Roche deal

AbVitro granted Roche exclusive rights to primer extension-based target enrichment (PETE) technology and associated patent applications. AbVitro and Roche scientists will collaborate on the development and application of the PETE technology, which will be used...